The discovery of peptide drugs for the treatment of CKD has attracted wide attention, with fibroin peptide notably ameliorating adriamycin-induced nephropathy by regulating lipid metabolism through the PANX1-PPARα/PANK1 pathway (Li S. S. et al., 2024). Here, PANX1 is linked to chronic kidney disease.